Masahiro Kodani

Tottori, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Curette-Assisted Removal of a Bronchial Screw Foreign Body Refractory to Forceps Grasping.

Curette-Assisted Removal of a Bronchial Screw Foreign Body Refractory to Forceps Grasping.

Journal: Respirology case reports

Published: May 15, 2026

Promising Effectiveness of Combined Chemotherapy and Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Real-World Prospective Observational Study (CS-Lung-003).

Promising Effectiveness of Combined Chemotherapy and Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Real-World Prospective Observational Study (CS-Lung-003).

Journal: Acta medica Okayama

Published: June 27, 2025

Speckled antinuclear antibody pattern as a potential predictor for immune-related adverse events in cancer patients.

Speckled antinuclear antibody pattern as a potential predictor for immune-related adverse events in cancer patients.

Journal: International journal of clinical oncology

Published: May 04, 2025

Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study.

Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study.

Journal: Respiratory investigation

Published: April 02, 2025

IgG4-related pleuritis diagnosed by local anesthesia thoracoscopy; a case report and literature review.

IgG4-related pleuritis diagnosed by local anesthesia thoracoscopy; a case report and literature review.

Journal: Respiratory medicine case reports

Published: April 01, 2025

Pseudo-hyperprogression of Malignant Pleural Mesothelioma Treated with Nivolumab.

Pseudo-hyperprogression of Malignant Pleural Mesothelioma Treated with Nivolumab.

Journal: Internal medicine (Tokyo, Japan)

Published: February 09, 2025

Successful Switch to Afatinib and Osimertinib Rechallenge with Corticosteroids after Osimertinib-induced Interstitial Lung Disease: A Case Report and Literature Review.

Successful Switch to Afatinib and Osimertinib Rechallenge with Corticosteroids after Osimertinib-induced Interstitial Lung Disease: A Case Report and Literature Review.

Journal: Internal medicine (Tokyo, Japan)

Published: February 02, 2025

Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry.

Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry.

Journal: JTO clinical and research reports

Published: January 23, 2025

Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.

Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.

Journal: Thoracic cancer

Published: May 21, 2024

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study.

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study.

Journal: ESMO open

Published: April 11, 2024

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.

Journal: Journal of cancer research and clinical oncology

Published: November 22, 2023

A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.

A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 05, 2023

Showing 1-12 of 34

Last Updated: 09/26/2026